[Cardio-pulmonary disorders associated with collagen vascular disease]. 2009

Hiroki Mizoguchi, and Hiromi Matsubara
Division of Cardiology, National Hospital Organization Okayama Medical Center.

Among the cardio-pulmonary disorders associated with collagen vascular disease (CVD), pulmonary arterial hypertension (PAH) is recognized as most serious problem. Because PAH is difficult to manage and its prognosis is terribly poor. Thus, early diagnosis of PAH in CVD is important. Since PAH patients associated with CVD are often asymptomatic in their early stage, screening with echocardiography is needed. The degree of inflammation causing PAH through endothelial injury is closely associated with CVD, and thus, the improvement of PAH may be achieved by immunosuppressant, especially in its early stage. Once the diagnosis of PAH is confirmed, treatment with oral vasodilators should be started as soon as possible. If oral vasodilators prove inadequate, intravenous epoprostenol should be administered without hesitating.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D003095 Collagen Diseases Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494) Collagen Disease,Disease, Collagen,Diseases, Collagen
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014652 Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. Disease, Vascular,Diseases, Vascular,Vascular Disease
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D042241 Early Diagnosis Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME. Early Detection of Disease,Diagnosis, Early,Disease Early Detection

Related Publications

Hiroki Mizoguchi, and Hiromi Matsubara
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Hiroki Mizoguchi, and Hiromi Matsubara
January 2007, Clinical and experimental rheumatology,
Hiroki Mizoguchi, and Hiromi Matsubara
January 1986, Kokyu to junkan. Respiration & circulation,
Hiroki Mizoguchi, and Hiromi Matsubara
February 1979, Southern medical journal,
Hiroki Mizoguchi, and Hiromi Matsubara
May 1990, Human pathology,
Hiroki Mizoguchi, and Hiromi Matsubara
July 1969, Nihon rinsho. Japanese journal of clinical medicine,
Hiroki Mizoguchi, and Hiromi Matsubara
February 2014, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,
Hiroki Mizoguchi, and Hiromi Matsubara
January 1992, Annual review of medicine,
Hiroki Mizoguchi, and Hiromi Matsubara
March 1999, Comprehensive therapy,
Hiroki Mizoguchi, and Hiromi Matsubara
March 2002, The European respiratory journal,
Copied contents to your clipboard!